1) OBSERVATION: The frequencies are changing. I would have to assess stats on the electromagnetic field to see its fluctuations. All I know is, I am highly sensitive to energy/frequencies, and they are changing, because…

Here is another very enjoyable conversation, with @Pandata19’s scientific advisory board member, Dr Jay Bhattacharya. Key ideas in this thread.

We are making world-changing decisions on the basis of evidence that is not very good. Vast scientific evidence tells us that infection fatality rates are much lower than originally expected. A small fraction of people get severe illness. 2/10

The scientific community has been resistant to evidence not supporting the majoritarian view, preferring instead to gin up panic, focusing on the worst case for everything the virus does & the best case for everything lockdowns do, and ignoring the range of uncertainty. 3/10

Academe is a strange place now, with debate stifled. But there's a sense some are opening up to considering opposing views. This is key, since suppression of views stops knowledge from progressing—the end of science. Public health norms of unified messaging complicate this. 4/10

Why did we, from the start, assume we knew nothing about this virus, instead of assuming a reasonable prior? Low susceptibility was evident early on. Assuming any virus is new is hard to square with our deep-time co-evolution with viruses, & their slow evolution. 5/10

With @franklowery our new study on attributes of T cells that contribute to successful cell therapy in cancer patients in @ScienceMagazine today w/ colleagues @slgoff_SB, @NCI_CCR_SB @theNCI a TL;DR thread on key findings with caveats :) 1/10

has a long history of using tumor infiltrating T cells (TILs) to treat cancers since well.. before I was even born. We analyzed our most successful melanoma ACT trial for cell surface phenotypes in TIL infusion products of patients (aPD1/immunotherapy naive) /2

Surprisingly we found a CD39- TIL subset (CD39-CD69-, DN) associated with ACT-response. TBH we were expecting the opposite (CD39+). We only included CD39 bcz multiple groups (e.g. Simoni et al, 2018) had reported CD39+ as enriching for anti-tumor/neoantigen reactive T cells. /3

CD39- DN TILs RNA/epigenetics resemble stem-like memory progenitors, and in vitro were able to self-renew, and give rise to other CD39+ subsets. OTOH the most dominant subset of patient infusion products were CD39+ CD69+ (DP) and these guys were terminally differentiated.. /4

So, to clarify we specifically analyzed tumor-specific mutation-reactive Tcells. Turns out, ACT-responders had pool of neoantigen-reactive TILs in the CD39- phenotype, while non-responders did not (despite other irrelevant CD39- Tcells) -> not all CD39- T cells are bystanders /5

Neonicotinoids and why they need to stay banned 🐝

#SciComm #ScienceTwitter #SaveTheBees #ClimateEmergency #ClimateCrisis

Neonicotinoids were banned by the EU in 2018 following multiple scientific studies which proved their severe detrimental impact on pollinators. Effects from neonics include reduced immune function, reduced foraging capabilities, and impaired cognition in bees.

The government has approved neonics for emergency use as a seed treatment on sugar beet. Yields have been impacted by beet yellows, transmitted by aphids. They argue that, because sugar beet does not flower and will not attract pollinators, the risk from neonics is acceptable.

Since the ban on neonics in 2018, the infection rate of beet yellows has increased year on year. Aphid populations have been proliferating due to mild winters, with no agrochemicals to solve the problem.

Sounds like a good case for neonics, right?

But this is the start of a vicious cycle. Climate change isn't going away. Winters will continue to get milder, resulting in the need for more and more pesticides to combat growing pest problems. Inevitably, this won't be the last time neonics are authorised for emergency use.